Skip to content

Randomized controlled trial of Yishentongluo therapy in treating diabetes kidney disease by stages

Randomized controlled trial of Yishentongluo therapy in treating diabetes kidney disease by stages

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400083561
Enrollment
Unknown
Registered
2024-04-28
Start date
2024-05-01
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic kidney disease

Interventions

the experimental group:Western standard treatment with Yishentongluo therapy
the control group:Western standard treatment

Sponsors

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meets the diagnostic, staging, and syndrome determination criteria for DKD; 2. Age between 18 and 75 years (including 18 and 75 years old); 3. eGFR=15ml/min/1.73m2; 4. Glycated hemoglobin (HbA1c)<= 9.0%; 5. Has not ever received renal replacement therapy; 6. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. With non-diabetic kidney disease; 2. Severe infection, anemia, or electrolyte imbalance in the previous four weeks; 3. Patients with acute kidney injury, oliguria or anuria, severe edema, massive pleural or peritoneal effusion; 4. Use of corticosteroids or immunosuppressants in the previous three months; 5. Severe cardiac, cerebral, hepatic, or hemorrhagic diseases, including stroke, transient ischemic attack, significant neurological dysfunction remaining after stroke, myocardial infarction, unstable angina, ischemic heart disease with coronary artery bypass or PCI surgery, congestive heart failure (cardiac function class III-IV, NYHA rating), hepatic inadequacy with aspartate transaminase(AST) or alanine aminotransferase (ALT) levels more than twice the normal upper limit, severe thrombocytopenia (PLT <10×10^9/L, abnormal coagulation, or active gastrointestinal bleeding; 6. Accompanied with consumptive diseases such as tuberculosis or a history of psychiatric diseases; 7. Pregnant or women preparing for pregnancy or lactation; 8. Individuals who are currently participating in other intervention clinical trials or have participated in other clinical trials within 12 weeks.

Design outcomes

Primary

MeasureTime frame
24-hour urinary protein;Estimated glomerular filtration rate (eGFR);

Secondary

MeasureTime frame
UACR, Scr;Traditional Chinese Medicine symptom score;

Countries

China

Contacts

Public ContactMengdi Wang

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University

wangmengdi@bjzhongyi.com+86 150 1127 3611

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026